GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AC Immune SA (NAS:ACIU) » Definitions » Valuation Rank

ACIU (AC Immune) Valuation Rank


View and export this data going back to 2016. Start your Free Trial

What is AC Immune Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

AC Immune Valuation Rank Related Terms

Thank you for viewing the detailed overview of AC Immune's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

AC Immune Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AC Immune SA (NAS:ACIU) » Definitions » Valuation Rank
Comparable Companies
ELDN PLX VYGR FHTX INBX CRGX LXRX SLNCF TVGN SGMO VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
IMR:Germany
Address
EPFL Innovation Park, Building B, Lausanne, CHE, 1015
Website
https://www.acimmune.com
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.